ProCE Banner Series

A Master Class in Personalized Myelofibrosis Care: Applying New Evidence and Novel Therapeutic Strategies to Improve Outcomes

Join us in-person for this CME-certified satellite symposium held in conjunction with the American Society of Hematology (ASH) Annual Meeting in San Diego, California, featuring expert perspectives on personalized myelofibrosis care. Bring your questions for the live Q&A session with the expert faculty at the end of the session.

To Register:  Please click the green “Learn More” button below. On the next page, select either Register for In-Person Event or Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

Friday Satellite Symposium on A Master Class in Personalized Myelofibrosis Care: Applying New Evidence and Novel Therapeutic Strategies to Improve Outcomes, preceding the 65th ASH Annual Meeting and Exposition

  AMA
Who Should Attend

This program is intended for physicians and other healthcare professionals who care for patients with myelofibrosis.

All Events

A Master Class in Personalized Myelofibrosis Care: Applying New Evidence and Novel Therapeutic Strategies to Improve Outcomes

Past Events

December

08

2023

11:30 AM - 1:30 PM Pacific Time (PT)

In-personVirtual

Marriott Marquis San Diego Marina, 333 W Harbor Dr., San Diego, California 92101

Faculty

ProCE Banner Faculty
Jean-Jacques Kiladjian, MD, PhD

Professor
Department of Clinical Pharmacology
Université de Paris
Professor
Clinical Investigations Center
Saint-Louis Hospital
Paris, France

ProCE Banner Faculty
Abdulraheem Yacoub, MD

Professor
The Division of Hematologic Malignancies and Cellular Therapeutics
University of Kansas Medical Center
The University of Kansas Health System
Westwood, Kansas

Topics

  • Partnering with Patients to Improve Outcomes and Quality of Life
  • Selecting Initial Treatment for Patients with Myelofibrosis
  • Recognizing Patterns of Suboptimal Response to First Line Myelofibrosis Treatment
  • Beyond the First Line: Disease Progression or Intolerance to Initial Therapy
  • A Look to the Future: What’s on the Horizon in Myelofibrosis Treatment

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
This program will improve learners’ knowledge, confidence, competence, and performance in using evidence-based and guideline-directed best practices in the care of patients with myelofibrosis. 

Target Audience
This program is intended for physicians and other healthcare professionals who care for patients with myelofibrosis. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify factors that contribute to cancer health disparities and may negatively affect outcomes for patients with MF
  • Incorporate available therapies into a best-practice strategy for first-line treatment of patients with MF based on available data and expert recommendations, taking risk stratification, molecular features, cytogenetics, and symptom burden into account
  • Plan evidence-based second-line therapeutic strategies for patients with MF who are relapsed, refractory, or intolerant to prior JAK inhibitor therapy
  • Assess the toxicity profiles of current and emerging MF therapies to formulate an adverse event management plan to support quality of life and continuation of treatment
  • Recall new data on emerging agents to aid discussions of ongoing trial opportunities with eligible patients

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from CTI BioPharma Corp., Geron Corporation, GlaxoSmithKline LLC, and Karyopharm Therapeutics Inc.